FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1864746645> ?p ?o ?g. }

• W1864746645 endingPage "e1850" @default.
• W1864746645 startingPage "e1850" @default.
• W1864746645 abstract "Tyrosine kinase inhibitors (TKIs) have shown strong activity against non-small-cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations. However, a fraction of EGFR wild-type (WT) patients may have an improvement in terms of response rate and progression-free survival when treated with erlotinib, suggesting that factors other than EGFR mutation may lead to TKI sensitivity. However, at present, no sufficiently robust clinical or biological parameters have been defined to identify WT-EGFR patients with greater chances of response. Therapeutics validation has necessarily to focus on lung cancer stem cells (LCSCs) as they are more difficult to eradicate and represent the tumor-maintaining cell population. Here, we investigated erlotinib response of lung CSCs with WT-EGFR and identified EGFR phosphorylation at tyrosine1068 (EGFRtyr1068) as a powerful biomarker associated with erlotinib sensitivity both in vitro and in preclinical CSC-generated xenografts. In contrast to the preferential cytotoxicity of chemotherapy against the more differentiated cells, in EGFRtyr1068 cells, erlotinib was even more active against the LCSCs compared with their differentiated counterpart, acquiring potential value as CSC-directed therapeutics in the context of WT-EGFR lung cancer. Although tumor growth was inhibited to a similar extent during erlotinib or chemotherapy administration to responsive tumors, erlotinib proved superior to chemotherapy in terms of higher tolerability and reduced tumor aggressiveness after treatment suspension, substantiating the possibility of preferential LCSC targeting, both in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) tumors. We conclude that EGFRtyr1068 may represent a potential candidate biomarker predicting erlotinib response at CSC-level in EGFR-WT lung cancer patients. Finally, besides its invariable association with erlotinib sensitivity in EGFR-WT lung CSCs, EGFRtyr1068 was associated with EGFR-sensitizing mutations in cell lines and patient tumors, with relevant diagnostic, clinical and therapeutic implications." @default.
• W1864746645 created "2016-06-24" @default.
• W1864746645 creator A5004342071 @default.
• W1864746645 creator A5023710153 @default.
• W1864746645 creator A5023848359 @default.
• W1864746645 creator A5028581226 @default.
• W1864746645 creator A5029232262 @default.
• W1864746645 creator A5042097944 @default.
• W1864746645 creator A5042925990 @default.
• W1864746645 creator A5047812860 @default.
• W1864746645 creator A5048934823 @default.
• W1864746645 creator A5057975103 @default.
• W1864746645 creator A5077791396 @default.
• W1864746645 creator A5079355038 @default.
• W1864746645 creator A5082807376 @default.
• W1864746645 date "2015-08-06" @default.
• W1864746645 modified "2023-10-16" @default.
• W1864746645 title "Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer" @default.
• W1864746645 cites W1891990202 @default.
• W1864746645 cites W1921623349 @default.
• W1864746645 cites W1964497970 @default.
• W1864746645 cites W1975992482 @default.
• W1864746645 cites W1976212312 @default.
• W1864746645 cites W1994599132 @default.
• W1864746645 cites W2000024168 @default.
• W1864746645 cites W2013614359 @default.
• W1864746645 cites W2020600748 @default.
• W1864746645 cites W2022881840 @default.
• W1864746645 cites W2025861423 @default.
• W1864746645 cites W2027640690 @default.
• W1864746645 cites W2043696829 @default.
• W1864746645 cites W2047004048 @default.
• W1864746645 cites W2047639006 @default.
• W1864746645 cites W2050093720 @default.
• W1864746645 cites W2062427160 @default.
• W1864746645 cites W2066565546 @default.
• W1864746645 cites W2072693879 @default.
• W1864746645 cites W2075204007 @default.
• W1864746645 cites W2077091211 @default.
• W1864746645 cites W2085433103 @default.
• W1864746645 cites W2088093215 @default.
• W1864746645 cites W2088594738 @default.
• W1864746645 cites W2089899771 @default.
• W1864746645 cites W2089912248 @default.
• W1864746645 cites W2095496928 @default.
• W1864746645 cites W2097026987 @default.
• W1864746645 cites W2098763217 @default.
• W1864746645 cites W2100912832 @default.
• W1864746645 cites W2101995865 @default.
• W1864746645 cites W2108614046 @default.
• W1864746645 cites W2111662961 @default.
• W1864746645 cites W2112535219 @default.
• W1864746645 cites W2125195105 @default.
• W1864746645 cites W2126755208 @default.
• W1864746645 cites W2129360604 @default.
• W1864746645 cites W2131152510 @default.
• W1864746645 cites W2138297714 @default.
• W1864746645 cites W2156228829 @default.
• W1864746645 cites W2158310399 @default.
• W1864746645 cites W2160982674 @default.
• W1864746645 cites W2163974863 @default.
• W1864746645 doi "https://doi.org/10.1038/cddis.2015.217" @default.
• W1864746645 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4558509" @default.
• W1864746645 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26247735" @default.
• W1864746645 hasPublicationYear "2015" @default.
• W1864746645 type Work @default.
• W1864746645 sameAs 1864746645 @default.
• W1864746645 citedByCount "38" @default.
• W1864746645 countsByYear W18647466452016 @default.
• W1864746645 countsByYear W18647466452017 @default.
• W1864746645 countsByYear W18647466452018 @default.
• W1864746645 countsByYear W18647466452019 @default.
• W1864746645 countsByYear W18647466452021 @default.
• W1864746645 countsByYear W18647466452022 @default.
• W1864746645 countsByYear W18647466452023 @default.
• W1864746645 crossrefType "journal-article" @default.
• W1864746645 hasAuthorship W1864746645A5004342071 @default.
• W1864746645 hasAuthorship W1864746645A5023710153 @default.
• W1864746645 hasAuthorship W1864746645A5023848359 @default.
• W1864746645 hasAuthorship W1864746645A5028581226 @default.
• W1864746645 hasAuthorship W1864746645A5029232262 @default.
• W1864746645 hasAuthorship W1864746645A5042097944 @default.
• W1864746645 hasAuthorship W1864746645A5042925990 @default.
• W1864746645 hasAuthorship W1864746645A5047812860 @default.
• W1864746645 hasAuthorship W1864746645A5048934823 @default.
• W1864746645 hasAuthorship W1864746645A5057975103 @default.
• W1864746645 hasAuthorship W1864746645A5077791396 @default.
• W1864746645 hasAuthorship W1864746645A5079355038 @default.
• W1864746645 hasAuthorship W1864746645A5082807376 @default.
• W1864746645 hasBestOaLocation W18647466451 @default.
• W1864746645 hasConcept C121608353 @default.
• W1864746645 hasConcept C126322002 @default.
• W1864746645 hasConcept C143998085 @default.
• W1864746645 hasConcept C2776256026 @default.
• W1864746645 hasConcept C2777506169 @default.
• W1864746645 hasConcept C2778087573 @default.
• W1864746645 hasConcept C2779438470 @default.
• W1864746645 hasConcept C2780580887 @default.

• next